CompletedNCT00677781Updated Sep 7, 2011

Impact of Microparticles on Postoperative Complications in Surgical Patients

An observational study in Neoplasm, Hepatic, Pancreatic Neoplasms and Colorectal Neoplasms, sponsored by University of Bern. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-07.

Sponsored by University of Bern · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 108
Ages: 18 Years and older
Sex: All

Study summary

Microparticles are cellular fragments which are released actively or passively under conditions of inflammation and stress. The impact of surgical operations on quantity and quality of microparticles remains unknown. In this observatory study we investigate quantitative and qualitative aspects of microparticles during cardiac and abdominal operations.

Conditions studied

Neoplasm, Hepatic
Pancreatic Neoplasms
Colorectal Neoplasms

Browse trials for

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 108 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Bern is the lead sponsor of 207 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Patients undergoing cardiac or hepatobiliary or colorectal surgery. Setting: university hospital.

Inclusion criteria

Patients undergoing cardiac or abdominal operations with a minimum expected operative time of 2 hours

Exclusion criteria

Exclusion Criteria:

Laparoscopic operations
emergency operations

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 108 participants (actual)
Biospecimen retention: Samples without dna

Groups and cohorts

F64
We investigate a cohort of 20 consecutive patients undergoing hepatic or pancreatic surgery (Pilot study)

What researchers measure

Primary outcomes

Postoperative morbidity
Time frame: 30 days

Secondary outcomes

Hospital stay
Time frame: 30 days
Mortality
Time frame: 30 days

Study locations

1 site

Department of visceral and transplant surgery, Bern University Hospital
Bern, 3010, Switzerland

References and documents

Publications

Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest. 2004 Jun;34(6):392-401. doi: 10.1111/j.1365-2362.2004.01355.x. PubMed 15200490 ↗
Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007 May;21(3):157-71. doi: 10.1016/j.blre.2006.09.001. Epub 2006 Nov 22. PubMed 17118501 ↗
Fujimi S, Ogura H, Tanaka H, Koh T, Hosotsubo H, Nakamori Y, Kuwagata Y, Shimazu T, Sugimoto H. Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. J Trauma. 2002 Mar;52(3):443-8. doi: 10.1097/00005373-200203000-00005. PubMed 11901317 ↗
Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, Hack CE, Sturk A. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000 Feb 1;95(3):930-5. PubMed 10648405 ↗
Ogura H, Kawasaki T, Tanaka H, Koh T, Tanaka R, Ozeki Y, Hosotsubo H, Kuwagata Y, Shimazu T, Sugimoto H. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma. 2001 May;50(5):801-9. doi: 10.1097/00005373-200105000-00005. PubMed 11371835 ↗
Soriano AO, Jy W, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, Horstman LL, Kett DH, Schein RM, Ahn YS. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med. 2005 Nov;33(11):2540-6. doi: 10.1097/01.ccm.0000186414.86162.03. PubMed 16276178 ↗
Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, Mallat Z. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001 Nov 27;104(22):2649-52. doi: 10.1161/hc4701.100516. PubMed 11723013 ↗
Heloire F, Weill B, Weber S, Batteux F. Aggregates of endothelial microparticles and platelets circulate in peripheral blood. Variations during stable coronary disease and acute myocardial infarction. Thromb Res. 2003 Jun 1;110(4):173-80. doi: 10.1016/s0049-3848(03)00297-4. PubMed 14512078 ↗
Morel O, Hugel B, Jesel L, Lanza F, Douchet MP, Zupan M, Chauvin M, Cazenave JP, Freyssinet JM, Toti F. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost. 2004 Feb;91(2):345-53. doi: 10.1160/TH03-05-0294. PubMed 14961163 ↗
Morel O, Jesel L, Freyssinet JM, Toti F. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Thromb J. 2005 Oct 11;3:15. doi: 10.1186/1477-9560-3-15. PubMed 16219103 ↗
van der Zee PM, Biro E, Ko Y, de Winter RJ, Hack CE, Sturk A, Nieuwland R. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem. 2006 Apr;52(4):657-64. doi: 10.1373/clinchem.2005.057414. Epub 2006 Jan 26. PubMed 16439610 ↗
Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol. 2007 Aug-Sep;66(2-3):159-65. doi: 10.1111/j.1365-3083.2007.01984.x. PubMed 17635793 ↗
Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, Sasaki M, Yoshida T, Fujiyama Y. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol. 2005 Sep;100(9):2042-8. doi: 10.1111/j.1572-0241.2005.50381.x. PubMed 16128950 ↗
Chamouard P, Desprez D, Hugel B, Kunzelmann C, Gidon-Jeangirard C, Lessard M, Baumann R, Freyssinet JM, Grunebaum L. Circulating cell-derived microparticles in Crohn's disease. Dig Dis Sci. 2005 Mar;50(3):574-80. doi: 10.1007/s10620-005-2477-0. PubMed 15810645 ↗
Jimenez JJ, Jy W, Mauro LM, Horstman LL, Soderland C, Ahn YS. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol. 2003 Dec;123(5):896-902. doi: 10.1046/j.1365-2141.2003.04716.x. PubMed 14632781 ↗
Proulle V, Hugel B, Guillet B, Grunebaum L, Lambert T, Freyssinet JM, Dreyfus M. Circulating microparticles are elevated in haemophiliacs and non-haemophilic individuals aged <18 years. Br J Haematol. 2005 Nov;131(4):487-9. doi: 10.1111/j.1365-2141.2005.05792.x. PubMed 16281940 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Sep 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00677781
Lead sponsor: University of Bern
First posted: May 15, 2008
Start date: Feb 2008
Primary completion: Dec 2008
Completion: Jan 2010
Last update: Sep 7, 2011

Study contacts

Guido Beldi, MD

principal investigator · Bern University Hospital

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

University of Bern

Start the discussion